SPIRIVA HANDIHALER Rx
Generic Name and Formulations:
Tiotropium (as bromide monohydrate) 18mcg/cap; dry pwd in caps for oral inhalation; with inhaler device.
Boehringer Ingelheim Pharmaceuticals
Indications for SPIRIVA HANDIHALER:
Long-term maintenance treatment of bronchospasm due to COPD, including chronic bronchitis and emphysema. To reduce exacerbations of COPD.
2 inh of one capsule contents (18mcg) once daily, using HandiHaler inhalation device. Max: 2 inh/24hrs. Do not swallow caps.
Allergy to ipratropium.
Not for the relief of acute symptoms. Discontinue if immediate hypersensitivity reactions (eg, angioedema) or paradoxical bronchospasm occurs; consider alternative therapy. Monitor for signs/symptoms of worsening narrow-angle glaucoma or worsening urinary retention (esp. GI or GU obstruction). Moderate-to-severe renal impairment; monitor for anticholinergic effects. Allergy to atropine or its derivatives; monitor. HandiHaler: avoid getting powder into eyes; or allergy to milk proteins. Pregnancy. Nursing mothers.
Avoid other anticholinergics.
Upper respiratory tract infection, dry mouth, sinusitis, pharyngitis, bronchitis, cough, headache, non-specific chest pain, UTI, dyspepsia, rhinitis, other anticholinergic effects (eg, urinary retention, constipation, dysuria, tachycardia, blurred vision, glaucoma); paradoxical bronchospasm.
HandiHaler (caps w. inh device)—5, 30, 90; Respimat (cartridge w. inh device)—4g (60 inh)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|